X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (404) 404
Book Review (187) 187
Publication (18) 18
Book Chapter (5) 5
Magazine Article (2) 2
Book / eBook (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
inadequate glycemic control (388) 388
index medicus (307) 307
double-blind (306) 306
humans (286) 286
diabetes mellitus, type 2 - drug therapy (226) 226
type 2 diabetes (220) 220
dapagliflozin (186) 186
diabetes (171) 171
hypoglycemic agents - therapeutic use (170) 170
endocrinology & metabolism (162) 162
glucose (152) 152
metformin (135) 135
sodium-glucose transporter 2 - antagonists & inhibitors (134) 134
pharmacology & pharmacy (111) 111
male (109) 109
female (103) 103
glucosides - therapeutic use (101) 101
placebo-controlled trial (101) 101
add-on therapy (98) 98
hypoglycemic agents - adverse effects (96) 96
middle aged (92) 92
dextrose (90) 90
sglt2 inhibitor (89) 89
treatment outcome (80) 80
diabetes mellitus (77) 77
benzhydryl compounds - therapeutic use (76) 76
type 2 diabetes mellitus (74) 74
drug therapy (72) 72
hypoglycemic agents - pharmacology (72) 72
type-2 diabetes-mellitus (72) 72
insulin (71) 71
animals (68) 68
blood glucose - metabolism (68) 68
body-weight (68) 68
aged (67) 67
canagliflozin (66) 66
medicine, general & internal (66) 66
care and treatment (64) 64
hyperglycemia (64) 64
adult (62) 62
glucosides - adverse effects (59) 59
analysis (58) 58
internal medicine (58) 58
clinical trials (57) 57
diabetes mellitus, type 2 - blood (57) 57
hypoglycemic agents (57) 57
add-on (55) 55
mellitus (54) 54
safety (54) 54
blood pressure (53) 53
blood glucose - drug effects (52) 52
efficacy (52) 52
hypoglycemic agents - administration & dosage (52) 52
diabetes mellitus, type 2 - metabolism (51) 51
diabetes therapy (51) 51
sglt2 inhibitors (51) 51
benzhydryl compounds - adverse effects (49) 49
risk factors (49) 49
drug therapy, combination (48) 48
japanese patients (48) 48
metformin plus sulfonylurea (48) 48
blood-pressure (45) 45
glucose metabolism (45) 45
medicine & public health (44) 44
sodium-glucose transporter 2 - metabolism (43) 43
glucosides - administration & dosage (42) 42
sodium (42) 42
body weight (41) 41
insulin resistance (40) 40
sglt2 (40) 40
double-blind method (39) 39
monotherapy (39) 39
diabetes mellitus, type 2 - complications (38) 38
hypoglycemia (38) 38
glycated hemoglobin a - metabolism (37) 37
long-term efficacy (36) 36
benzhydryl compounds - administration & dosage (34) 34
patients (34) 34
randomized controlled trials as topic (34) 34
abridged index medicus (33) 33
dosage and administration (33) 33
glucose cotransporter 2 (33) 33
metformin - therapeutic use (33) 33
research (33) 33
glucosides - pharmacology (32) 32
glycosylated hemoglobin (32) 32
pharmacokinetics (32) 32
selective sglt2 inhibitor (32) 32
benzhydryl compounds (31) 31
empagliflozin (31) 31
glucose - metabolism (31) 31
blood pressure - drug effects (30) 30
health aspects (30) 30
hemoglobin (30) 30
hypoglycemic agents - pharmacokinetics (30) 30
endocrinology (29) 29
kidney - metabolism (29) 29
meta-analysis (29) 29
therapy (29) 29
diabetes mellitus, type 2 - physiopathology (28) 28
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


THE SHINSHU MEDICAL JOURNAL, ISSN 0037-3826, 2018, Volume 66, Issue 5, pp. 319 - 324
Objectives and Methods : The present study was performed to determine whether patients with HbA1c ≥ 7.0% can show improvement with additive treatments. A total... 
type 2 diabetes mellitus | clinical inertia | inadequate glycemic control
Journal Article
Journal Article
The Shinshu Medical Journal, ISSN 0037-3826, 2018, Volume 66, Issue 5, pp. 319 - 324
[Objectives and Methods :] The present study was performed to determine whether patients with HbA1c>-7.0% can show improvement with additive treatments. A... 
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 03/2012, Volume 156, Issue 6, pp. 405 - 415
Background: Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2, may improve glycemic control with a lower dose of insulin and attenuate the... 
Primary funding source: astrazeneca and bristol-myers squibb | MEDICINE, GENERAL & INTERNAL | SELECTIVE SGLT2 INHIBITOR | THERAPY | DOUBLE-BLIND | RISK | GLIMEPIRIDE | INADEQUATE GLYCEMIC CONTROL | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
DIABETES CARE, ISSN 0149-5992, 03/2014, Volume 37, Issue 3, pp. 740 - 750
Journal Article
Diabetologia, ISSN 0012-186X, 12/2013, Volume 56, Issue 12, pp. 2582 - 2592
The aim of this work was to evaluate the efficacy and safety of canagliflozin vs placebo and sitagliptin in patients with type 2 diabetes who were being... 
Sodium glucose co-transporter 2 (SGLT2) inhibitor | Medicine & Public Health | Human Physiology | Canagliflozin | Metabolic Diseases | Internal Medicine | Sitagliptin | Metformin | Type 2 diabetes mellitus | GLIPIZIDE | ADD-ON | SULFONYLUREA | DAPAGLIFLOZIN | MELLITUS | INADEQUATE GLYCEMIC CONTROL | DIET | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | 52-WEEK | INHIBITOR | Blood Pressure | Triazoles - administration & dosage | Triazoles - adverse effects | Thiophenes - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Pyrazines - administration & dosage | Glycated Hemoglobin A - drug effects | Body Weight - drug effects | Lipids | Male | Thiophenes - administration & dosage | Metformin - adverse effects | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Female | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Glucosides - adverse effects | Fasting | Treatment Outcome | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Glucosides - administration & dosage | Adolescent | Pyrazines - adverse effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Care and treatment | Body weight | Glucose | Comparative analysis | Dextrose | Index Medicus
Journal Article
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, ISSN 0931-0509, 11/2018, Volume 33, Issue 11, pp. 2005 - 2011
Background. The sodium-glucose co-transporter 2 inhibitor dapagliflozin decreases haemoglobin A1c (HbA1c), body weight, blood pressure (BP) and urinary... 
kidney | type 2 diabetes | SGLT2 inhibitor | dapagliflozin | diabetic nephropathy | LONG-TERM | METFORMIN | SGLT2 INHIBITORS | 28-WEEK EXTENSION | 24-WEEK | MELLITUS | INADEQUATE GLYCEMIC CONTROL | TRANSPLANTATION | DOUBLE-BLIND | CARDIOVASCULAR-DISEASE | UROLOGY & NEPHROLOGY | PLACEBO-CONTROLLED TRIAL | ORIGINAL ARTICLES | Editor's Choice
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2014, Volume 36, Issue 1, pp. 84 - 100.e9
Abstract Objective Dapagliflozin is a highly selective, orally active inhibitor of renal sodium-glucose cotransporter 2 that reduces hyperglycemia by... 
Internal Medicine | Medical Education | type 2 diabetes mellitus | glycemic control | SGLT2 | Asian | dapagliflozin | monotherapy | METFORMIN | EFFICACY | SGLT2 INHIBITOR | RISK | INADEQUATE GLYCEMIC CONTROL | BODY-WEIGHT | PHARMACOKINETICS | CANAGLIFLOZIN | HYPOGLYCEMIA | PHARMACOLOGY & PHARMACY | CUTOFF POINTS | Glycated Hemoglobin A - analysis | Hypoglycemic Agents - therapeutic use | Hypoglycemic Agents - pharmacokinetics | Prospective Studies | Benzhydryl Compounds | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Body Weight - drug effects | Male | Treatment Outcome | Glucosides - pharmacokinetics | Blood Glucose - drug effects | Asian Continental Ancestry Group | Reproductive Tract Infections - chemically induced | Glucosides - administration & dosage | Hypoglycemic Agents - administration & dosage | Urinary Tract Infections - chemically induced | Adult | Female | Glucosides - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemia - chemically induced | Type 2 diabetes | Glucose metabolism | Medical colleges | Medical research | Hyperglycemia | Physiological aspects | Clinical trials | Medicine, Experimental | Glucose | Dextrose | Diabetes therapy | Hepatitis | Disease | Womens health | Rodents | Rheumatic diseases | Values | Patient safety | Blood pressure | Diabetes | Kinases | Drug dosages | Index Medicus
Journal Article